Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Prognostic value of mismatch repair deficiency in patients with advanced gastric cancer, treated by surgery and adjuvant 5-fluorouracil and leucovorin chemoradiotherapy.

Kim SM, An JY, Byeon SJ, Lee J, Kim KM, Choi MG, Lee JH, Sohn TS, Bae JM, Kim S.

Eur J Surg Oncol. 2019 Aug 31. pii: S0748-7983(19)30659-6. doi: 10.1016/j.ejso.2019.08.025. [Epub ahead of print]

PMID:
31500870
2.

Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.

Smyth EC, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z, Fassan M, Rugge M, Valeri N, Okines A, Hewish M, Allum W, Stenning S, Nankivell M, Langley R, Cunningham D.

JAMA Oncol. 2017 Sep 1;3(9):1197-1203. doi: 10.1001/jamaoncol.2016.6762.

3.

[Correlations between DNA mismatch repair (MMR) and prognosis and prediction of treatment efficacy in stage II/II colon cancer].

Qin Q, Ying J, Lyu N, Guo L, Zhi W, Zhou A, Wang J.

Zhonghua Zhong Liu Za Zhi. 2014 Nov;36(11):844-8. Chinese.

PMID:
25620482
4.

The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study.

He EY, Hawkins NJ, Mak G, Roncolato F, Goldstein D, Liauw W, Clingan P, Chin M, Ward RL.

Oncologist. 2016 May;21(5):618-25. doi: 10.1634/theoncologist.2015-0530. Epub 2016 Mar 23.

5.

Adjuvant Chemotherapy Versus Chemoradiotherapy Versus Surgery Alone for Early Gastric Cancer with One or Two Lymph Node Metastasis.

Kim SM, An JY, Lee J, Sohn TS, Kim S.

Ann Surg Oncol. 2018 Jun;25(6):1616-1624. doi: 10.1245/s10434-018-6434-5. Epub 2018 Mar 22.

PMID:
29569127
6.

Small Bowel Adenocarcinoma Frequently Exhibits Lynch Syndrome-associated Mismatch Repair Protein Deficiency But Does Not Harbor Sporadic MLH1 Deficiency.

Xia M, Singhi AD, Dudley B, Brand R, Nikiforova M, Pai RK.

Appl Immunohistochem Mol Morphol. 2017 Jul;25(6):399-406. doi: 10.1097/PAI.0000000000000389.

PMID:
27258561
7.

Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients.

Lanza G, Gafà R, Santini A, Maestri I, Guerzoni L, Cavazzini L.

J Clin Oncol. 2006 May 20;24(15):2359-67.

PMID:
16710035
8.

Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.

Cheong JH, Yang HK, Kim H, Kim WH, Kim YW, Kook MC, Park YK, Kim HH, Lee HS, Lee KH, Gu MJ, Kim HY, Lee J, Choi SH, Hong S, Kim JW, Choi YY, Hyung WJ, Jang E, Kim H, Huh YM, Noh SH.

Lancet Oncol. 2018 May;19(5):629-638. doi: 10.1016/S1470-2045(18)30108-6. Epub 2018 Mar 19.

PMID:
29567071
9.

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

André T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T, Tabernero J, Van Laethem JL, Banzi M, Maartense E, Shmueli E, Carlsson GU, Scheithauer W, Papamichael D, Möehler M, Landolfi S, Demetter P, Colote S, Tournigand C, Louvet C, Duval A, Fléjou JF, de Gramont A.

J Clin Oncol. 2015 Dec 10;33(35):4176-87. doi: 10.1200/JCO.2015.63.4238. Epub 2015 Nov 2.

PMID:
26527776
10.

Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.

Hong YS, Nam BH, Kim KP, Kim JE, Park SJ, Park YS, Park JO, Kim SY, Kim TY, Kim JH, Ahn JB, Lim SB, Yu CS, Kim JC, Yun SH, Kim JH, Park JH, Park HC, Jung KH, Kim TW.

Lancet Oncol. 2014 Oct;15(11):1245-53. doi: 10.1016/S1470-2045(14)70377-8. Epub 2014 Sep 4.

PMID:
25201358
11.

Benefit of adjuvant chemoradiotherapy in patients with pathological stage III gastric cancer.

Ma GF, Zhang HG, Liu J, Chen YX, Xiao H, Wang XF, He J, Zeng ZC, Sun J, Liu TS.

Cancer Manag Res. 2019 Jul 2;11:6029-6041. doi: 10.2147/CMAR.S204887. eCollection 2019.

12.

Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).

Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, Enzinger PC, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Gunderson LL, Goldberg RM, Venook AP, Ilson D, O'Reilly E, Ciombor K, Berg DJ, Meyerhardt J, Mayer RJ.

J Clin Oncol. 2017 Nov 10;35(32):3671-3677. doi: 10.1200/JCO.2017.74.2130. Epub 2017 Oct 4.

13.

D2-resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy.

Peng J, Wei Y, Zhou F, Dai J, Zhong Y, Xie C, Qin Y, Gong J, Xiong B, Zhou Y.

Cancer Med. 2016 Oct;5(10):2773-2780. doi: 10.1002/cam4.873. Epub 2016 Sep 26.

14.

Mismatch Repair Gene Expression as a Predictor of Tumor Responses in Patients With Rectal Cancer Treated With Preoperative Chemoradiation.

Huh JW, Kim HC, Kim SH, Park YA, Cho YB, Yun SH, Lee WY, Park HC, Choi DH, Park JO, Park YS, Chun HK.

Medicine (Baltimore). 2016 Jan;95(3):e2582. doi: 10.1097/MD.0000000000002582.

15.

Immunohistochemistry and microsatellite instability analysis in molecular subtyping of colorectal carcinoma based on mismatch repair competency.

Yuan L, Chi Y, Chen W, Chen X, Wei P, Sheng W, Zhou X, Shi D.

Int J Clin Exp Med. 2015 Nov 15;8(11):20988-1000. eCollection 2015.

16.

Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.

Konstantinopoulos PA, Luo W, Liu JF, Gulhan DC, Krasner C, Ishizuka JJ, Gockley AA, Buss M, Growdon WB, Crowe H, Campos S, Lindeman NI, Hill S, Stover E, Schumer S, Wright AA, Curtis J, Quinn R, Whalen C, Gray KP, Penson RT, Cannistra SA, Fleming GF, Matulonis UA.

J Clin Oncol. 2019 Oct 20;37(30):2786-2794. doi: 10.1200/JCO.19.01021. Epub 2019 Aug 28.

PMID:
31461377
17.

Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.

Kokka F, Bryant A, Brockbank E, Powell M, Oram D.

Cochrane Database Syst Rev. 2015 Apr 7;(4):CD010260. doi: 10.1002/14651858.CD010260.pub2. Review.

PMID:
25847525
18.

Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.

Ohrling K, Edler D, Hallström M, Ragnhammar P.

Acta Oncol. 2010 Aug;49(6):797-804. doi: 10.3109/02841861003705786.

PMID:
20307245
19.

The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy.

Stiekema J, Trip AK, Jansen EP, Boot H, Cats A, Ponz OB, Verheij M, van Sandick JW.

Ann Surg Oncol. 2014 Apr;21(4):1107-14. doi: 10.1245/s10434-013-3397-4. Epub 2013 Dec 4.

PMID:
24306660
20.

Capecitabine-cisplatin versus 5-fluorouracil/leucovorin in combination with radiotherapy for adjuvant therapy of lymph node positive locally advanced gastric cancer.

Ustaalioglu BBO, Bilici A, Tilki M, Surmelioglu A, Erkol B, Figen M, Uyar S.

J Cancer Res Ther. 2018 Sep;14(Supplement):S736-S741. doi: 10.4103/0973-1482.183548.

Supplemental Content

Support Center